(Q44674375)

English

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Francesco Merli

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Stefano Luminari

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Fiorella Ilariucci

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Mario Petrini

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Carlo Visco

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Achille Ambrosetti

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Caterina Stelitano

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Francesco Caracciolo

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Nicola Di Renzo

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Francesco Angrilli

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Angelo M Carella

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Isabella Capodanno

12

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Elisa Barbolini

13

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sara Galimberti

14

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Massimo Federico

15

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Massimo Federico

16

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

7 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

156

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

346-353

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Patterns of survival in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08958.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08958.X

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44674375&oldid=2031539964"